– initially approved exports to Pakistan by Lucent Drugs were later banned by authorities.
– Despite this ban, approximately 13,800 kg of Tramadol worth ₹4.12 crore was illegally routed via Denmark’s CHR Olesen Pharmaceuticals and another 5,000 kg worth ₹1.34 crore via Malaysia-based SM Biomed.
– Illegal shipments generated revenue totaling ₹5.46 crore deposited into company accounts before being mixed with legitimate business funds to mask their origins.
This case highlights severe violations within India’s pharmaceutical export framework that could have wider implications concerning regulatory oversight and international narcotics trafficking controls. It demonstrates criminal misuse of legitimate business channels for unethical purposes-a matter that undermines trust in India’s pharmaceutical industry globally.
The involvement of foreign intermediaries suggests sophisticated coordination between domestic violators and international entities strategically exploiting legal loopholes post-ban enforcement measures. Tightening compliance monitoring might potentially be essential for safeguarding India’s reputation as a responsible drug exporter.
ED’s action underlines the importance of proactive judicial mechanisms like PMLA courts for addressing organized commercial crimes effectively while signaling future punitive measures against such malpractices.